F-15063
F-15,063 is an orally active potential antipsychotic, and an antagonist at the D2/D3 receptors, partial agonist at the D4 receptor, and agonist at the 5-HT1A receptors. It has greater efficacy at the 5-HT1A receptors than other antipsychotics, such as clozapine, aripiprazole, and ziprasidone. This greater efficacy may lead to enhanced antipsychotic properties, as antipsychotics that lack 5-HT1A affinity are associated with increased risk of extrapyramidal symptoms, and lack of activity against the negative symptoms of schizophrenia.
Link from a Wikipage to another Wikipage
primaryTopic
F-15063
F-15,063 is an orally active potential antipsychotic, and an antagonist at the D2/D3 receptors, partial agonist at the D4 receptor, and agonist at the 5-HT1A receptors. It has greater efficacy at the 5-HT1A receptors than other antipsychotics, such as clozapine, aripiprazole, and ziprasidone. This greater efficacy may lead to enhanced antipsychotic properties, as antipsychotics that lack 5-HT1A affinity are associated with increased risk of extrapyramidal symptoms, and lack of activity against the negative symptoms of schizophrenia.
has abstract
F-15,063 is an orally active p ...... d some antipsychotic activity.
@en
alternative name
F-15,063
@en
IUPAC name
N-{[3-(Cyclopent-1-en-1-yl)phe ...... zofuran-7-yl)oxy]ethan-1-amine
@en
Wikipage page ID
34,178,462
page length (characters) of wiki page
Wikipage revision ID
1,024,220,553
Link from a Wikipage to another Wikipage
ImageFile
@en
OtherNames
F-15,063
@en
PIN
N-{[3-phenyl]methyl}-2-[oxy]ethan-1-amine
@en
wikiPageUsesTemplate
subject
comment
F-15,063 is an orally active p ...... ive symptoms of schizophrenia.
@en
label
F-15063
@en